Phage Therapy in a 16-Year-Old Boy with Netherton Syndrome.

Pikria Zhvania, Naomi Sulinger Hoyle, Lia Nadareishvili, Dea Nizharadze, Mzia Kutateladze
Author Information
  1. Pikria Zhvania: Eliava Phage Therapy Center, Tbilisi, Georgia.
  2. Naomi Sulinger Hoyle: Eliava Phage Therapy Center, Tbilisi, Georgia.
  3. Lia Nadareishvili: Eliava Phage Therapy Center, Tbilisi, Georgia.
  4. Dea Nizharadze: Eliava Phage Therapy Center, Tbilisi, Georgia.
  5. Mzia Kutateladze: G. Eliava Institute of Bacteriophages, Microbiology and Virology, Tbilisi, Georgia.

Abstract

Netherton syndrome (NS) is a rare autosomal recessive disorder, characterized by a classical triad of clinical features, including congenital ichthyosiform erythroderma, trichorrhexis invaginata, and atopic diathesis coupled with frequent bacterial infections (1). The genetic basis for the disease has been recently identified with mutations in gene SPINK5, which is involved in the regulation of formation of skin barriers. We report on a 16-year-old male with all the typical manifestations of NS, including atopic diathesis and ongoing serious staphylococcal infections and allergy to multiple antibiotics whose family sought help at the Eliava Phage Therapy Center when all other treatment options were failing. Treatment with several antistaphylococcal bacteriophage preparations led to significant improvement within 7 days and very substantial changes in his symptoms and quality of life after treatment for 6 months, including return visits to the Eliava Phage Therapy Center after 3 and 6 months of ongoing use of phage at home.

Keywords

References

  1. Georgian Med News. 2011 Jul-Aug;(196-197):101-5 [PMID: 21873760]
  2. Viruses. 2015 Aug 20;7(8):4783-99 [PMID: 26308042]
  3. J Invest Dermatol. 2008 May;128(5):1148-59 [PMID: 17989726]
  4. FEMS Microbiol Lett. 2016 Jan;363(2):fnv225 [PMID: 26656541]
  5. Curr Pharm Biotechnol. 2010 Jan;11(1):69-86 [PMID: 20214609]
  6. Future Microbiol. 2015;10(5):685-8 [PMID: 26000644]
  7. J Exp Med. 1943 Sep 1;78(3):161-8 [PMID: 19871319]
  8. Microb Biotechnol. 2011 Sep;4(5):643-50 [PMID: 21481199]
  9. Biotechnol J. 2016 May;11(5):595-600 [PMID: 27008250]
  10. J Am Acad Dermatol. 2014 Sep;71(3):415.e1-415.e15 [PMID: 25128118]
  11. AMA Arch Derm. 1958 Oct;78(4):483-7 [PMID: 13582191]
  12. Virol Sin. 2015 Feb;30(1):80-1 [PMID: 25662889]
  13. Arch Dermatol. 1969 Nov;100(5):550-8 [PMID: 4242601]
  14. Cell Tissue Res. 2013 Feb;351(2):289-300 [PMID: 23344365]

Word Cloud

Created with Highcharts 10.0.0NethertonincludinginfectionsEliavaPhageTherapysyndromeNSatopicdiathesisongoingstaphylococcalCentertreatment6 monthsphagerareautosomalrecessivedisordercharacterizedclassicaltriadclinicalfeaturescongenitalichthyosiformerythrodermatrichorrhexisinvaginatacoupledfrequentbacterial1geneticbasisdiseaserecentlyidentifiedmutationsgeneSPINK5involvedregulationformationskinbarriersreport16-year-oldmaletypicalmanifestationsseriousallergymultipleantibioticswhosefamilysoughthelpoptionsfailingTreatmentseveralantistaphylococcalbacteriophagepreparationsledsignificantimprovementwithin7 dayssubstantialchangessymptomsqualitylifereturnvisits3usehome16-Year-OldBoySyndromeantibioticresistancebacteriophagespediatricstherapy

Similar Articles

Cited By